Randomized clinical trial comparing collagen plug and advancement flap for trans‐sphincteric anal fistula. BJS 2017; 104: 1160-1166.
Published: 10th May 2017
Authors: J. Bondi, J. Avdagic, U. Karlbom, O. Hallböök, D. Kalman, J. Šaltytė Benth et al.
The role of a collagen plug for treating anal fistula is not well established. A randomized prospective multicentre non‐inferiority study of surgical treatment of trans‐sphincteric cryptogenic fistulas was undertaken, comparing the anal fistula plug with the mucosal advancement flap with regard to fistula recurrence rate and functional outcome.
Patients with an anal fistula were evaluated for eligibility in three centres, and randomized to either mucosal advancement flap surgery or collagen plug, with clinical follow‐up at 3 and 12 months. The primary outcome was the fistula recurrence rate. Anal pain (visual analogue scale), anal incontinence (St Mark's score) and quality of life (Short Form 36 questionnaire) were also reported.
Ninety‐four patients were included; 48 were allocated to the plug procedure and 46 to advancement flap surgery. The median follow‐up was 12 (range 9–24) months. The recurrence rate at 12 months was 66 per cent (27 of 41 patients) in the plug group and 38 per cent (15 of 40) in the flap group (
There was a considerably higher recurrence rate after the anal fistula plug procedure than following advancement flap repair. Registration number:
You may also be interested in
Authors: M.E. Kelly, R. Glynn, A.G.J. Aalbers, M. Abraham‐Nordling, W. Alberda, A. Antoniou et al.
Notes: Complete resection is key
Randomized clinical trial
Randomized clinical trial of intracutaneously versus transcutaneously sutured ileostomy to prevent stoma‐related complications (ISI trial).
Authors: M. F. Sier, D. D. Wisselink, D. T. Ubbink, R. J. Oostenbroek, G. J. Veldink, B. Lamme et al.
Notes: More leaks with intracutaneous
Authors: S. J. Chapman, A. Pericleous, C. Downey, D. G. Jayne
Notes: No easy answers.
Randomized clinical trial
Authors: E. M. de Leede, N. J. van Leersum, H. M. Kroon, V. van Weel, J. R. M. van der Sijp, B. A. Bonsing et al.
Notes: Chewing gum no effect on recovery
Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. BJS 2018; 105: e204-e211.
Authors: I. Ubink, W. J. van Eden, P. Snaebjornsson, N. F. M. Kok, J. van Kuik, W. M. U. van Grevenstein et al.
Notes: Mesenchymal subtype predominates
Authors: E. J. Ryan, E. M. Creagh
Effect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer. BJS 2018; 105: e192-e203.
Authors: F. C. Koyama, C. M. Lopes Ramos, F. Ledesma, V. A. F. Alves, J. M. Fernandes, B. B. Vailati et al.
Notes: Molecular enhancement of treatment
Clinicopathological, genomic and immunological factors in colorectal cancer prognosis. BJS 2018; 105: e99-e109.
Authors: K. M. Marks, N. P. West, E. Morris, P. Quirke
Notes: Defines modern practice
Gut microbiome influences on anastomotic leak and recurrence rates following colorectal cancer surgery. BJS 2018; 105: e131-e141.
Authors: S. Gaines, C. Shao, N. Hyman, J. C. Alverdy
Notes: A neglected frontier
Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer. BJS 2018; 105: e110-e120.
Authors: O. Nordgård, K. Tjensvoll, B. Gilje, K. Søreide
Notes: The inner space frontier
Growth rates of pulmonary metastases after liver transplantation for unresectable colorectal liver metastases. BJS 2018; 105: 295-301.
Authors: H. Grut, S. Solberg, T. Seierstad, M. E. Revheim, T. S. Egge, S. G. Larsen et al.
Notes: Immunosuppression may not accelerate growth
Preliminary results of a cohort study of induction chemotherapy‐based treatment for locally recurrent rectal cancer. BJS 2018; 105: 447-452.
Authors: D. M. G. I. van Zoggel, S. J. Bosman, M. Kusters, G. A. P. Nieuwenhuijzen, J. S. Cnossen, G. J. Creemers et al.
Notes: Promising responses